Education
About Us
Working with TipRanks
Follow Us
Aura Biosciences Inc (AURA)
NASDAQ:AURA
AURA Stock Chart & Stats
$5.60
-$0.11(-1.36%)
At close: 4:00 PM EST
$5.60
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$4.35 - $8.27
Previous CloseN/A
Volume82.15K
Average Volume (3M)302.40K
Market Cap
$355.62M
Enterprise Value$325.82M
Total Cash (Recent Filing)$161.87M
Total Debt (Recent Filing)$17.75M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Mar 31, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding63,503,270
10 Day Avg. Volume325,525
30 Day Avg. Volume302,397
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.03
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-365.68
Enterprise Value/Ebitda-3.05
Forecast
1Y Price Target
$19.33Price Target Upside245.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationBel-sar's photosensitive payload has shown induction of local immune memory in early patients, which could produce durable tumor control and reduce recurrence risk after local therapy.
Regulatory AlignmentOrphan Drug designations from FDA and EMA plus an FDA Fast Track designation for bel-sar in early choroidal melanoma support an expedited development path and strengthen regulatory credibility.
Trial Execution And Market OpportunitySteady Phase 3 CoMpass enrollment, broad prescreening activity and an estimated ocular oncology addressable population support a clear path to a meaningful commercial opportunity if primary endpoints are met.
Bears Say
Competitive Pressure In Bladder CancerThe non-muscle invasive bladder cancer (NMIBC) landscape is crowded in later, higher-risk settings, which could limit bel-sar's uptake and make achieving differentiated market share more difficult.
Competitive Risk In Uveal MelanomaA strong competing therapy showing activity in slightly larger uveal melanoma tumors could shrink the addressable patient population and complicate adoption of bel-sar in ocular oncology.
Funding Runway And Dilution RiskApproximately one and a half years of cash runway increases the likelihood of near-term financing needs that could lead to dilution or constrain ongoing investment in clinical programs.
Aura Biosciences Inc News
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $4.34 and its highest was $8.27 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $355.62M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is Mar 31, 2026 which is in 57 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on Nov 13, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.464 by $0.064.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -0.43.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 63,503,270 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.464. Following the earnings report the stock price went down -0.718%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aura Biosciences Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.33 (245.18% Upside)
$19.33 (245.18% Upside)
Insider Transactions
Sold Shares
Worth $182.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.89%
12-Months-Change
Fundamentals
Return on Equity
-64.26%
Trailing 12-Months
Asset Growth
-6.36%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
AURA Stock 12 Month Forecast
Average Price Target
$19.33
▲(245.18% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
3.25% Insiders
8.04% Mutual Funds
0.12% Other Institutional Investors
80.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---